Who owns Kymera?
Kymera has been owned by affiliates of palladium equity partners, llc (collectively, “palladium”), a middle market private equity firm with over $3 billion in assets under management, since 2018. Palladium equity partners acquires kymera international and 5n’s antimony powder assets. The single platform is rebranded to promote global products, established as kymera international.Established in 1876, Kymera International has carved a niche in the metal industry with its pioneering solutions and long-standing expertise.Kymera International’s top competitors include Keronite, Cirrus Materials Science, and 3M.
Is Kymera public?
Kymera Therapeutics has successfully priced a public offering of $250. The offering includes both common stock and pre-funded warrants, indicating strong investor interest and flexibility in financing options. The average price target for Kymera Therapeutics is 61. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $70. The average price target represents 40. Increase from the current price of $43.